198 related articles for article (PubMed ID: 15004724)
1. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
Chan KT; Lung ML
Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
[TBL] [Abstract][Full Text] [Related]
2. Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells.
Li YX; Lin ZB; Tan HR
Acta Pharmacol Sin; 2004 Jan; 25(1):76-82. PubMed ID: 14704126
[TBL] [Abstract][Full Text] [Related]
3. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
Dong-Dong L; Xi-Ran Z
Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
[TBL] [Abstract][Full Text] [Related]
4. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
Tsang WP; Kwok TT
Oncogene; 2007 Jul; 26(33):4877-81. PubMed ID: 17297456
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
6. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro.
Lai PB; Chi TY; Chen GG
Apoptosis; 2007 Feb; 12(2):387-93. PubMed ID: 17191126
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin Sensitizes Mutant p53 (R248Q)-Expressing Hepatocellular Carcinoma Cells to Doxorubicin by Inhibiting P-gp Expression.
Yang Y; He J; Chen J; Lin L; Liu Y; Zhou C; Su Y; Wei H
Biomed Res Int; 2019; 2019():8207056. PubMed ID: 31976328
[TBL] [Abstract][Full Text] [Related]
8. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
Li B; Ye T; Zhao L; Li DH; Gou XH; Zhao LY; Han L; Chen L; Yan LN; Gong JP
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
[TBL] [Abstract][Full Text] [Related]
9. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Fantappiè O; Solazzo M; Lasagna N; Platini F; Tessitore L; Mazzanti R
Cancer Res; 2007 May; 67(10):4915-23. PubMed ID: 17510421
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
[TBL] [Abstract][Full Text] [Related]
12. TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin.
Jiang C; Pecha J; Hoshino I; Ankrapp D; Xiao H
Cancer Res; 2007 Apr; 67(8):3574-82. PubMed ID: 17440068
[TBL] [Abstract][Full Text] [Related]
13. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53.
Niu J; Xu Z; Li XN; Han Z
Cell Biol Int; 2007 Feb; 31(2):156-64. PubMed ID: 17097318
[TBL] [Abstract][Full Text] [Related]
14. [Effects of hepatitis B virus X gene on p21(WAF1) expression through p53-dependent and p53-independent pathways].
Lin J; Zhu MH; Qu JH; Li FM; Ni CR
Ai Zheng; 2004 Jul; 23(7):749-55. PubMed ID: 15248906
[TBL] [Abstract][Full Text] [Related]
15. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
Kubicka S; Trautwein C; Niehof M; Manns M
Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
[TBL] [Abstract][Full Text] [Related]
16. A chenodeoxycholic derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells.
Park SE; Lee SW; Hossain MA; Kim MY; Kim MN; Ahn EY; Park YC; Suh H; Kim GY; Choi YH; Kim ND
Cancer Lett; 2008 Oct; 270(1):77-86. PubMed ID: 18554781
[TBL] [Abstract][Full Text] [Related]
17. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein.
Wurzer G; Herceg Z; Wesierska-Gadek J
Cancer Res; 2000 Aug; 60(15):4238-44. PubMed ID: 10945636
[TBL] [Abstract][Full Text] [Related]
18. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.
Chang FL; Lai MD
J Urol; 2001 Jul; 166(1):304-10. PubMed ID: 11435891
[TBL] [Abstract][Full Text] [Related]
19. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
Zhou J; Cheng SC; Luo D; Xie Y
Biochem Biophys Res Commun; 2001 Feb; 280(5):1237-42. PubMed ID: 11162660
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.
Jung EU; Yoon JH; Lee YJ; Lee JH; Kim BH; Yu SJ; Myung SJ; Kim YJ; Lee HS
Cancer Lett; 2010 Dec; 298(1):9-15. PubMed ID: 20573444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
